Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.

Shindiapina, Polina; Alinari, Lapo

Shindiapina, Polina; Alinari, Lapo.

Afiliación

Shindiapina P; Department of Internal Medicine, Division of Hematology, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH, USA.
Alinari L; Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, 410 West 12th Avenue, 481A Wiseman Hall, Columbus, Ohio, 43210, USA.

Ther Adv Hematol ; 9(4): 89-105, 2018 Apr.

Article en En | MEDLINE | ID: mdl-29623180

Palabras clave

Hodgkin's lymphoma; checkpoint inhibitor therapy; pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Ther Adv Hematol Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google